Emanuela Pozzi

434 total citations
5 papers, 90 citations indexed

About

Emanuela Pozzi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Emanuela Pozzi has authored 5 papers receiving a total of 90 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 2 papers in Oncology and 1 paper in Genetics. Recurrent topics in Emanuela Pozzi's work include Lung Cancer Treatments and Mutations (2 papers), Immunotherapy and Immune Responses (1 paper) and Peptidase Inhibition and Analysis (1 paper). Emanuela Pozzi is often cited by papers focused on Lung Cancer Treatments and Mutations (2 papers), Immunotherapy and Immune Responses (1 paper) and Peptidase Inhibition and Analysis (1 paper). Emanuela Pozzi collaborates with scholars based in Switzerland, France and United States. Emanuela Pozzi's co-authors include Roger Henriksson, Olivier Chinot, Josep Garcia, Frank Saran, Warren Mason, Wolfgang Wick, Ryo Nishikawa, Timothy F. Cloughesy, Sai‐Hong Ignatius Ou and Isabell R. Loftin and has published in prestigious journals such as Annals of Oncology, Neuro-Oncology and Journal of Thoracic Oncology.

In The Last Decade

Emanuela Pozzi

5 papers receiving 86 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emanuela Pozzi Switzerland	3	48	37	26	26	22	5	90
Ziad Thotathil New Zealand	7	26 0.5×	33 0.9×	29 1.1×	11 0.4×	24 1.1×	13	112
Franciszek Szubstarski Poland	5	61 1.3×	75 2.0×	18 0.7×	20 0.8×	10 0.5×	8	100
Dan Christian Chiforeanu France	4	49 1.0×	20 0.5×	54 2.1×	28 1.1×	46 2.1×	5	93
Brett T. Brinker United States	5	23 0.5×	41 1.1×	46 1.8×	27 1.0×	65 3.0×	5	133
E. Razis Greece	5	24 0.5×	27 0.7×	18 0.7×	11 0.4×	13 0.6×	20	76
Donata Sartori Italy	6	36 0.8×	72 1.9×	15 0.6×	51 2.0×	22 1.0×	18	126
C. Ang Canada	4	39 0.8×	25 0.7×	33 1.3×	12 0.5×	47 2.1×	5	107
Edward Y. Zhu United States	5	26 0.5×	28 0.8×	11 0.4×	24 0.9×	16 0.7×	13	73
Christine Waibel Switzerland	7	77 1.6×	55 1.5×	16 0.6×	9 0.3×	37 1.7×	12	118
Kaylee M. Keller Netherlands	8	62 1.3×	34 0.9×	15 0.6×	13 0.5×	43 2.0×	10	190

Countries citing papers authored by Emanuela Pozzi

Since Specialization

Citations

This map shows the geographic impact of Emanuela Pozzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emanuela Pozzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emanuela Pozzi more than expected).

Fields of papers citing papers by Emanuela Pozzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emanuela Pozzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emanuela Pozzi. The network helps show where Emanuela Pozzi may publish in the future.

Co-authorship network of co-authors of Emanuela Pozzi

This figure shows the co-authorship network connecting the top 25 collaborators of Emanuela Pozzi. A scholar is included among the top collaborators of Emanuela Pozzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emanuela Pozzi. Emanuela Pozzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Felip, Enriqueta, Mauricio Burotto, Zanete Zvirbule, et al.. (2021). Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer. Clinical Pharmacology in Drug Development. 10(10). 1142–1155. 15 indexed citations

2.

Mok, Tony, Solange Peters, D. Ross Camidge, et al.. (2020). Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. Journal of Thoracic Oncology. 16(2). 259–268. 29 indexed citations

3.

Quaquarini, Erica, Federico Sottotetti, Anna Gambaro, et al.. (2017). Comorbidity scores as predictive tools for nivolumab toxicity in patients with advanced non small cell lung cancer (NSCLC): preliminary results of a prospective multicenter study. Annals of Oncology. 28. vi60–vi60. 1 indexed citations

4.

Saran, Frank, Olivier Chinot, Roger Henriksson, et al.. (2016). Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-Oncology. 18(7). 991–1001. 43 indexed citations

5.

Gandola, Lorenza, et al.. (1979). Ifosfamide in the treatment of bronchogenic carcinoma. A preliminary trial.. PubMed. 25(1). 41–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact